Tegaserod Maleate, CAS number 189188-57-6, is an efficacious treatment for patients suffering from both chronic idiopathic constipation and Irritable Bowel Syndrome with constipation. Known by it’s trade name Zelnorm, which was marketed by Novartis, this drug was removed from the U.S. market in 2007, amid concerns of adverse cardiovascular side effects. Despite the recall and discontinuation of Zelzorm in the U.S. and Canada, over twenty five countries continue to market generic tegaserod maleate, sometimes under the name Zelmac.
As a 5-HT4-receptor agonist, tegaserod maleate is effective as it imitates the action of the neurotransmitter serotonin, of which a large percentage of serotonin in the body is found in the gastrointestinal tract. By aiding the muscles of the digestive tract, tegaserod maleate also helps to move food through more quickly, relieving constipation. This decrease in nerve sensitivity leads to decreased feelings of pain and bloating as well. Reported side effects of tegaserod maleate include headache, diarrhea, flatulence, fatigue, hemorrhoids, and abdominal pain.
Offered in 2 and 6 milligram tablets, tegaserod maleate has proven to be a formidable, short term treatment for women who have irritable bowel syndrome (IBS) with constipation as their main bowel problem. This same efficacy has not been proven in men studied with similar conditions. Tegaserod Maleate is also proven to be a viable treatment in patients younger than 65 years of age with chronic idiopathic constipation, lasting at least six months or longer. In 2011 the Neurogastroenterology & Motility (NMO) Journal online offered positive information that was reported in an article titled “Influence of tegaserod on proximal gastric tone and on the perception of gastric distention in functional dyspepsia.” This article, which detailed the randomized and controlled trial, involving 30 male patients with abnormalities in gastric sensorimotor function, thus leading to functional dyspepsia. The trial results indicated that a significantly enhanced meal-induced accommodation was found with patients who received tegaserod maleate. While further research is underway regarding the use of tegaserod maleate for patients with chronic constipation, strides continue to be made using this one of a kind drug. LGM Pharma provides tegaserod maleate for research and development purposes, and offers support to clients throughout the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.